Human Epididymis Protein 4 in Women With Severe Preeclampsia / HELLP Syndrome

Prognostic Value of Human Epididymis Protein 4 (HE4) for Persistent Proteinuria in Women With Severe Preeclampsia / HELLP Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03891394

Enrollment

110

Registered

2019-03-27

Start date

2019-04-01

Completion date

2019-10-30

Last updated

2019-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Brief summary

Pre-eclampsia seems to be associated with a four to five times increase risk of later microalbuminuria and CKD which might suggest a possible direct renal damage from pre-eclampsia

Interventions

DIAGNOSTIC_TESTHuman epididymis protein 4

Human epididymis protein 4 serum level in predicting persistent proteniuria

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Inclusion criteria

1. Pregnant women 18-35 years old. 2. Fulfilling the criteria for diagnosis of sever preeclampsia. 3. Fulfilling the criteria for diagnosis of HELLP syndrome

Exclusion criteria

1. Diabetes mellitus 2. Preexisting renal disease. 3. Chronic hypertension 4. Rheumatologic diseases 5. Adnexal mass.

Design outcomes

Primary

Measure	Time frame	Description
protein in urine	12 weeks postpartum	proteinuria \> 0.3 mg protein / mg creatinine.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026